216 related articles for article (PubMed ID: 29268035)
21. Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Yokote K; Terauchi Y; Nakamura I; Sugamori H
Expert Opin Pharmacother; 2016 Oct; 17(15):1995-2003. PubMed ID: 27477242
[TBL] [Abstract][Full Text] [Related]
22. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Nakamura I; Maegawa H; Tobe K; Uno S
Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
[TBL] [Abstract][Full Text] [Related]
23. Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring.
Wada N; Mori K; Nakagawa C; Sawa J; Kumeda Y; Shoji T; Emoto M; Inaba M
J Diabetes Complications; 2015; 29(8):1310-3. PubMed ID: 26298521
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan.
Ishida Y; Murayama H; Shinfuku Y; Taniguchi T; Sasajima T; Oyama N
Expert Opin Drug Saf; 2020 May; 19(5):625-631. PubMed ID: 32228183
[No Abstract] [Full Text] [Related]
25. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
[TBL] [Abstract][Full Text] [Related]
27. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.
Bryson A; Jennings PE; Deak L; Paveliu FS; Lawson M
Expert Opin Pharmacother; 2016 Jul; 17(10):1309-16. PubMed ID: 27181910
[TBL] [Abstract][Full Text] [Related]
29. Teneligliptin for the treatment of type 2 diabetes.
Goda M; Kadowaki T
Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
[TBL] [Abstract][Full Text] [Related]
30. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
[TBL] [Abstract][Full Text] [Related]
31. Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Maegawa H; Tobe K; Tabuchi H; Nakamura I
Expert Opin Pharmacother; 2016 Oct; 17(15):1985-94. PubMed ID: 27463414
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Teneligliptin a DPP4 Inhibitor in Terms of Efficacy and Safety with Respect to QT/QTc Prolongation in Patients with Type II Diabetes Mellitus (T2DM).
Bhosle D; Chandekar B; Alimuddin S
J Assoc Physicians India; 2022 May; 70(5):11-12. PubMed ID: 35598125
[TBL] [Abstract][Full Text] [Related]
33. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
[TBL] [Abstract][Full Text] [Related]
35. Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
Haneda M; Kadowaki T; Ito H; Sasaki K; Hiraide S; Ishii M; Matsukawa M; Ueno M
Diabetes Ther; 2018 Jun; 9(3):1083-1097. PubMed ID: 29637459
[TBL] [Abstract][Full Text] [Related]
36. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance.
Ito T; Naito Y; Shimmoto N; Ochiai K; Hayashi N; Okamura T
Expert Opin Drug Saf; 2021 Mar; 20(3):363-372. PubMed ID: 33269625
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Nakamura I; Maegawa H; Tobe K; Tabuchi H; Uno S
Expert Opin Pharmacother; 2018 Feb; 19(3):189-201. PubMed ID: 29185822
[TBL] [Abstract][Full Text] [Related]
40. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Kitada M; Ogura Y; Nitta K; Fujii M; Kanasaki K; Konishi K; Iida Y; Nakagawa A; Koya D
J Diabetes Investig; 2019 May; 10(3):706-713. PubMed ID: 30136384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
